GSK's ViiV unit adds new HIV drug to Aids patent pool
Published on Apr 2, 2014 7:35 AM
LONDON (REUTERS) - GlaxoSmithKline's Aids drugs business is to add one of its latest HIV medicines to a patent pool - cutting its future price for developing countries and pooling intellectual property rights.
ViiV Healthcare, which is majority owned by the British drugmaker, said the agreement covered dolutegravir, a new anti-retroviral medicine, for use in both adults and children with the human immunodeficiency virus (HIV) that causes Aids.
The move is a further victory for the new Medicines Patent Pool (MPP), which is trying to convince major drugmakers around the world to share rights to important medicines for developing countries with makers of cheap generic drugs.
"Dolutegravir is an innovative HIV therapy, and we will be working closely with generic manufacturers over the next few years to make it available to those most in need as quickly as possible," the MPP's executive director Greg Perry said in a statement announcing the agreement.
To continue reading, log in if you are a subscriber
If you are not a subscriber, you can get instant, unlimited access here